View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
October 8, 2021

Inhalon initiates Phase I Covid-19 inhaled therapy trial

The trial is being conducted along with Celltrion and will analyse inhaled IN-006’s safety and tolerability in healthy subjects. 

Inhalon Biopharma has initiated the Phase I clinical trial of its inhaled drug, IN-006, in healthy individuals, with the dosing of the first subject.

IN-006 is a muco-trapping form of a human monoclonal antibody, regdanvimab (CT-P59).

Being carried in partnership with Celltrion, the placebo-controlled, dose-escalation Phase I trial will analyse the safety and tolerability of inhaled IN-006.

In May this year, Inhalon received $7m award from the US Army Medical Research & Development Command (USAMRDC) to assess inhaled IN-006 in the Phase I trial.

The muco-trapping antibody platform of Inhalon traps the virus in airway mucus, hindering the local spread of infection.

Furthermore, it can rapidly remove the virus from the lungs using the natural ability of the body to clear mucus.

Inhaled treatment can be administered by people at home and broaden vital treatment supplies to more patients by lowering the dosage required.

It also lowers the requirement on healthcare workers and infusion clinic space needed for intravenous (IV) therapies.

Inhalon Biopharma president and CEO John Whelan said: “Inhalon’s muco-trapping antibody technology is the only therapeutic modality that can actively clear infectious virus from the lungs via natural mucus clearance, thereby eliminating the source of inflammation and viral spread.

“Combining Inhalon’s inhaled, muco-trapping platform with Celltrion’s highly effective anti-SARS-CoV2 antibody will likely create a new treatment that patients can self-administer to free up valuable healthcare resources.”

Celltrion has already obtained emergency use authorization (EUA) for the IV formulation of regdanvimab to treat Covid-19 in various nations globally.

In a Phase III trial conducted by Celltrion, regdanvimab showed to substantially lower the risk of Covid-19-associated hospitalisation or mortality by 72% in people who are at increased risk of disease progression.

The drug offered a 70% reduced risk in the trial for all subjects.

In addition, regdanvimab was found to be efficacious against variants including the Alpha, Beta, Gamma and Delta variants of SARS-CoV-2 in in vitro or in vivo studies.

Related Companies

Free Whitepaper

Unlocking the clinical trial potential of Africa

Ongoing improvements around infrastructure, continued investment, and being home to one of the world’s largest working age populations, means that Africa’s role in the clinical trials market has transformed. In this whitepaper, Oximio outlines the dynamics of today’s clinical trial market in Africa, including the key challenges the region is facing and how sponsors can overcome them to unlock the continent’s growing potential.
by Oximio
Enter your details here to receive your free Whitepaper.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy